84 related articles for article (PubMed ID: 25555075)
1. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
Med Lett Drugs Ther; 2015 Jan; 57(1459):e8. PubMed ID: 25555075
[No Abstract] [Full Text] [Related]
2. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
3. FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
Deisseroth A; Ko CW; Nie L; Zirkelbach JF; Zhao L; Bullock J; Mehrotra N; Del Valle P; Saber H; Sheth C; Gehrke B; Justice R; Farrell A; Pazdur R
Clin Cancer Res; 2015 Mar; 21(5):950-4. PubMed ID: 25601959
[TBL] [Abstract][Full Text] [Related]
4. Castleman's disease and sarcoidosis, a rare association resulting in a "mixed" response: a case report.
Mohammed A; Janku F; Qi M; Kurzrock R
J Med Case Rep; 2015 Feb; 9():45. PubMed ID: 25884809
[TBL] [Abstract][Full Text] [Related]
5. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA
BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
[TBL] [Abstract][Full Text] [Related]
6. Siltuximab for multicentric Castleman disease.
Liu YC; Stone K; van Rhee F
Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
[TBL] [Abstract][Full Text] [Related]
7. Dose selection of siltuximab for multicentric Castleman's disease.
Mayer CL; Xie L; Bandekar R; Qi M; van de Velde H; Reddy M; Qin X; Davis HM; Puchalski TA
Cancer Chemother Pharmacol; 2015 May; 75(5):1037-45. PubMed ID: 25784388
[TBL] [Abstract][Full Text] [Related]
8. What Is the best treatment for HIV-associated multicentric Castleman disease?
Bower M; Dalla Pria A
Clin Adv Hematol Oncol; 2012 Mar; 10(3):207-9. PubMed ID: 22402432
[No Abstract] [Full Text] [Related]
9. The first reported case and management of multicentric Castleman's disease associated with Kaposi's sarcoma in an HIV-2-infected patient.
Bouvresse S; Marcelin AG; Franck N; Regnier S; Damond F; Tulliez M; Dupin N
AIDS; 2007 Jul; 21(11):1492-4. PubMed ID: 17589201
[No Abstract] [Full Text] [Related]
10. Multicentric Castleman's disease & HIV infection.
Cotter A; Lambert J; O'Gorman P
Ir Med J; 2009 Oct; 102(9):294-5. PubMed ID: 19902650
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Casper C; Chaturvedi S; Munshi N; Wong R; Qi M; Schaffer M; Bandekar R; Hall B; van de Velde H; Vermeulen J; Reddy M; van Rhee F
Clin Cancer Res; 2015 Oct; 21(19):4294-304. PubMed ID: 26124203
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid for treatment of multicentric Castleman's disease.
Rieu P; Droz D; Gessain A; Grünfeld JP; Hermine O
Lancet; 1999 Oct; 354(9186):1262-3. PubMed ID: 10520638
[TBL] [Abstract][Full Text] [Related]
13. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases.
Buchler T; Dubash S; Lee V; Chilton D; Cartledge J; Isaacson P; Tedder RS; Lee SM
AIDS; 2008 Aug; 22(13):1685-7. PubMed ID: 18670234
[No Abstract] [Full Text] [Related]
14. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman's disease.
Lin Q; Fang B; Huang H; Yu F; Chai X; Zhang Y; Zhou J; Xia Q; Li Y; Song Y
Blood Cancer J; 2015 Mar; 5(3):e298. PubMed ID: 25794134
[No Abstract] [Full Text] [Related]
15. HIV-associated Castleman's disease: from case reports to evidence.
Bazeos A; Powles T; Stebbing J
J HIV Ther; 2007 Sep; 12(3):61-2. PubMed ID: 17962792
[No Abstract] [Full Text] [Related]
16. Complete remission with anti-CD20 therapy for unicentric, non-HIV-associated, hyaline-vascular type, Castleman's disease.
Estephan FF; Elghetany MT; Berry M; Jones DV
Cancer Invest; 2005; 23(2):191. PubMed ID: 15813512
[No Abstract] [Full Text] [Related]
17. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
18. [Castleman's disease, HIV and rituximab].
Valencia ME; López V; Corcuera MT; Del Val D
Rev Clin Esp; 2012 Feb; 212(2):118-9. PubMed ID: 21924712
[No Abstract] [Full Text] [Related]
19. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
[TBL] [Abstract][Full Text] [Related]
20. [Castleman's disease: the problems of diagnosis and treatment].
Sukhodolia AI; Chubar IV; Sukhodolia SA; Hryshchuk OV
Klin Khir; 2012 Jul; (7):63-4. PubMed ID: 23033784
[No Abstract] [Full Text] [Related]
[Next] [New Search]
